（编辑 丛可心） 证券日报网讯 1月6日，美好医疗发布公告称，公司股票2026年1月5日、6日连续两个交易日收盘价格涨 幅偏离值累计达40.32%（超过30%），触发异常波动。公司核查后表示，前期披露信息无需更正，经营 正常，未发现未公开重大信息，控股股东及董监高在波动期间未买卖股票，不存在应披露未披露事项。 ...

Group 1 - The brain-computer interface (BCI) concept stocks have experienced a surge, with 20 stocks hitting the daily limit up for two consecutive days, indicating strong market interest in companies involved in this sector [2][19][21] - The Shanghai Composite Index has reached a ten-year high, marking the 13th consecutive trading day of gains, suggesting a new upward trend in the A-share market [20][21] - Notable BCI stocks that have hit the daily limit include Innovation Medical, Rock Mountain Technology, Sanbo Brain Science, and others, reflecting the growing popularity of this sector [20][21] Group 2 - The Sai Ling International Investment Fund (Shanghai) has invested in several leading companies in the BCI field, including Shanghai Brain Tiger Technology, Beijing Pinchi Medical, and Beijing Brain Land Technology, indicating a strong focus on top-tier technology in this industry [22][31] - Shanghai Brain Tiger Technology is recognized as a leader in the invasive BCI sector, having developed a unique high-throughput flexible BCI technology and achieved significant clinical milestones [24][28] - Beijing Pinchi Medical specializes in invasive BCI technology and has developed a rechargeable directional Bluetooth perceivable brain pacemaker, which has been recognized as one of the top innovations in the BCI field [29][12] Group 3 - Beijing Brain Land Technology is the first company to focus on consumer-grade BCIs, with a strong emphasis on non-invasive BCI research and development, and has received multiple patents for its products [14][32] - Huake Precision (Beijing) Medical Equipment Co., Ltd. is a high-tech enterprise in the neurosurgery field, focusing on the development of medical electrodes and BCI technology, with several medical device registrations [33][16] - Beijing Mind Ark Technology Development Co., Ltd. has developed a near-infrared brain function imaging system, showcasing significant technological advantages in various applications, including mental health and brain-machine interfaces [34][17]

Core Viewpoint - The medical sector is experiencing significant activity, particularly driven by advancements in brain-computer interface (BCI) technology, which is attracting investor interest and leading to substantial market movements in related stocks and ETFs [3][10][11]. Market Performance - On January 6, 2026, the largest medical ETF (512170) saw a recovery, closing up 1.12% with a total trading volume of 1.017 billion yuan, marking two consecutive days of trading over 1 billion yuan [1][8]. - The ETF's index, which includes 12 related concept stocks, has a combined weight exceeding 36%, indicating strong sector representation [11][13]. Stock Highlights - Brain-computer interface stocks, such as Sanbo Brain Science and Meihua Medical, reached their daily limit up, while stocks like Yingke Medical and Hejing Biological experienced declines [1][8]. - The BCI sector is expected to see increased valuations for related listed companies, potentially boosting market financing and capital development [3][10]. Technological Advancements - A recent breakthrough in BCI technology was reported by Fudan University Huashan Hospital, which successfully completed the first clinical trial of a fully implanted, wireless, and functional BCI product [3][10]. - The BCI technology is positioned as a key area of investment, with potential applications in disease treatment and long-term enhancements for humans, opening up a market space worth trillions [10][11]. Investment Insights - According to CITIC Construction Investment, the current valuation of the medical index is 34.28 times, which is below the 70% threshold of the past decade, suggesting a favorable investment opportunity [4][11]. - The medical ETF (512170) is recognized as an efficient tool for accessing core medical assets, with a total size exceeding 26.4 billion yuan, making it the largest medical ETF in the market [6][13].

1月6日，三大指数集体收涨，两市成交额高达2.81万亿。其中，上证指数高开高走，收涨1.50%，报 4083.67点，刷新2015年7月底以来新高。并实现日线13连阳，创史上最长连阳记录。 回顾A股历史，上证指数10连阳以上的行情十分罕见。仅在1992年2月25日至3月11日实现12连阳，以及 分别在1992年5月、2006年6月、2017年12月至2018年1月录得三次11连阳。 梳理发现，指数连阳行情往往伴随后续趋势性上涨。上证指数曾在2006年6月实现11连阳后，便开始持 续攀升，最终在2007年10月突破6000点大关，期间累计涨幅超260%。 从板块表现来看，6日市场热点板块全面开花。脑机接口概念涨幅居前，三博脑科、美好医疗、创新医 疗2连板；商业航天概念持续爆发，十余只成分股涨停，鲁信创投8天6板，北斗星通、中国卫通6天4 板。分析指出，科技牛是2025年贯穿全年的一个重要特征，2026年科技牛行情有望继续延续。 而本轮上证指数的强势表现早有端倪。2025年全年，上证指数累计上涨18.41%，深证成指上涨 29.87%，创业板指更是大涨近50%。 2026年第一个交易日，上证指数延续涨势收涨1.3 ...

Market Performance - The A-share market opened the year with a strong performance, with the Shanghai Composite Index achieving a rare 13 consecutive days of gains, closing at a ten-year high of 4083.67 points, up 1.5% [2] - The Shenzhen Component Index and the ChiNext Index also saw increases of 1.4% and 0.75% respectively, indicating a broad market rally [2] - Over 140 stocks hit the daily limit up, and the total trading volume exceeded 2.8 trillion yuan [1][2] Sector Performance - The commercial aerospace sector showed significant strength, with multiple stocks hitting the daily limit up, including Luxin Venture Capital and Beidou Star Communication [2] - The brain-computer interface concept also saw a surge, with stocks like Sanbo Brain Science and Meihao Medical achieving consecutive gains [2] - The financial sector collectively rose, with companies like Hualin Securities and Dazhihui hitting the daily limit up [2] - The non-ferrous metals sector was active, with companies like Luoyang Molybdenum and Zijin Mining reaching historical highs [2] Economic Factors - Analysts attribute the strong performance of the A-share market to multiple positive factors, including improved market sentiment post-New Year and expectations of long-term capital inflows from insurance funds [3] - The macroeconomic growth policies and anticipated industry policy details related to new productivity have also contributed to the rising index [3] Company Highlights - Zijin Mining's stock rose over 6%, closing with a gain of 6.21%, leading to a market capitalization exceeding 1 trillion yuan, making it the first mining company in A-shares to reach this milestone [4] - Zijin Mining expects a net profit of approximately 51-52 billion yuan for 2025, a year-on-year increase of about 59%-62%, driven by increased production of key minerals [4] - The rise in international gold prices, influenced by geopolitical tensions, has also positively impacted Zijin Mining's performance [5] Consumer Market Impact - The increase in international gold prices has led to domestic jewelry brands like Chow Sang Sang raising their gold jewelry prices by 200 to 1500 yuan [6][8] - The price of gold jewelry is expected to continue rising, reflecting a structural change in consumer preferences towards smaller, high-design products and investment gold products [8] Market Outlook - Goldman Sachs has maintained an "overweight" rating on the A-share market, projecting a target increase of 15%-20% for the Shanghai Composite Index in 2026 [9] - Other institutions also express optimism for the A-share market, predicting a transition from valuation recovery in 2025 to profit-driven growth in 2026 [9]

证券代码：301363 证券简称：美好医疗 公告编号：2026-001 深圳市美好创亿医疗科技股份有限公司 关于公司股价异动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）股票（证券代码： 301363，证券简称：美好医疗）2026年1月5日、6日连续两个交易日收盘价格涨幅偏 离值累计达到40.32%（超过30％），根据深圳证券交易所的有关规定，属于股票交 易异常波动的情形。 二、公司关注及核实情况说明 4、经核实，公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项。 5、在公司本次股票异常波动期间，不存在公司控股股东、实际控制人及公司董 事买卖公司股票的情况。 三、是否存在应披露而未披露信息的说明 公司董事会确认，除在指定媒体已公开披露的信息外，公司目前没有任何根据 《深圳证券交易所创业板股票上市规则》等有关规定应予以披露而未披露的事项或 1 与该事项有关的筹划、商谈、意向、协议等；董事会也未获悉公司有根据《深圳证 券交 ...

2026年首个交易日，A股市场迎来"开门红"，上证指数重新站上4000点。1月6日，上证指数又走出13连 阳的新纪录，报收4083.67点，再创十年新高；两市及北交所共4101只股票上涨。 从板块来看，脑机接口概念延续强势，十余只成分股涨停，三博脑科、美好医疗、创新医疗2连板。被 视为"牛市旗手"或"市场风向标"的券商股强劲上行，华林证券冲上涨停，华安证券、东北证券等多股大 涨。有色金属板块表现活跃，洛阳钼业、紫金矿业等多股创历史新高。商业航天概念反复活跃。 这种从"模式创新"向"底层技术创新"的偏好反转，体现了投资者对中国经济高质量发展的坚定信心。科 技不再是市场的点缀，而是成为了定盘星，重构了资本市场的估值体系与成长逻辑。 与此同时，作为"牛市旗手"的券商股与作为"价值压舱石"的有色金属板块交相辉映，构成了市场上涨的 双翼。券商股的爆发，折射出市场信心的全面修复以及对资本市场制度改革红利的预期；而洛阳钼业、 紫金矿业等资源巨头创下历史新高，则反映了在全球通胀预期与工业硬需求下，中国核心资产在全球配 置中的独特性与稀缺性。 这种"科技领航、金融助攻、资源筑底"的良性互动，标志着市场进入了一个更加成熟、更加均 ...

Core Viewpoint - The A-share market saw a collective rise in its three major indices, with the Shanghai Composite Index reaching a ten-year high, driven by strong performance in the brain-computer interface sector [1] Group 1: Market Performance - On January 6, the A-share market indices collectively rose, with the Shanghai Composite Index opening high and continuing to climb [1] - The brain-computer interface concept stocks maintained strong momentum, with companies like Beikang and Sanbo Brain Science hitting their daily price limits [1] Group 2: Company Developments - Elon Musk announced via social media that his company Neuralink plans to start large-scale production of brain-computer interface devices by December 31, 2026, and will advance nearly fully automated surgical procedures [1] - Merge Labs, a startup co-founded by OpenAI CEO Sam Altman, announced its spin-off to focus on non-invasive brain signal reading technology using ultrasound, aiming for broader and more precise interpretation without electrode implantation [1] Group 3: Industry Insights - According to a report by Guokai Securities, brain-computer interfaces are at the forefront of artificial intelligence technology and are expected to accelerate applications in medical, mental health, rehabilitation, and health management sectors with policy support [1] - Since 2025, both domestic and international AI technologies, products, and commercial applications have rapidly developed, with the pharmaceutical industry being a key application area, indicating significant potential for AI in drug development, auxiliary diagnosis, and services [1]

Investment Rating - The investment rating for the brain-computer interface (BCI) industry is "Outperform the Market" (maintained) [1] Core Insights - The BCI industry is at a critical juncture of transitioning from technological breakthroughs to commercialization, driven by policies, technology advancements, and application scenarios. The global market is expected to experience explosive growth due to favorable policies, production expectations from companies like Neuralink, and clinical breakthroughs in China [3] - The report emphasizes focusing on core segments of the industry chain and technology routes, prioritizing companies with competitive advantages. Upstream, attention should be on hardware suppliers like EEG sensors and core chips; midstream, companies with key patents and clinical resources, especially in invasive technologies; and downstream, tracking companies that form commercial closed loops in rehabilitation and industrial control [3] Summary by Sections 1. Definition and Classification of BCI - BCI is defined as a direct communication link between brain electrical activity and external devices, used for reading or writing neural signals. It is categorized into invasive, semi-invasive, non-invasive, and interventional types [12][10] 2. Relevant Policies - The BCI industry is increasingly recognized in China, with policies like the "Implementation Opinions on Promoting the Innovation and Development of the BCI Industry" issued in July 2025, indicating a strategic focus on BCI as a national emerging industry [19][20] 3. Industry Overview - The BCI industry is transitioning from clinical trials to commercialization, with significant advancements in invasive BCI technologies led by companies like Neuralink. The report highlights the rapid development of non-invasive BCIs due to algorithm improvements and data accumulation [26][34] 4. Relevant Companies - Key players in the invasive BCI sector include Neuralink, which has conducted clinical trials and aims to decode language intentions by 2025. Other notable companies include Precision Neuroscience and Synchron, which are also making strides in the BCI field [46][49] 5. Investment Opportunities - The report identifies investment opportunities in companies that are developing BCI technologies across various applications, including rehabilitation, consumer electronics, and industrial safety. The focus is on companies that can navigate the regulatory landscape and demonstrate clinical efficacy [32][48]

脑机接口概念股，热度持续！ 今日（1月6日），A股三大指数集体收涨，A股连续两日超100只个股涨停。截至今日收盘，沪指涨1.5%，报 4083.67点，创10年新高；深证成指涨1.4%，报14022.55点；创业板指涨0.75%，报3319.29点。个股涨多跌少， 超4100股上涨，涨停个股达到120家（不含ST股）。全市场成交额超2.8万亿元，创三个月新高。 继昨日集体大涨后，脑机接口概念股今日再度走强。截至今日收盘，Wind脑机接口指数涨幅超过4%，通达信 人脑工程指数涨幅接近5%，三博脑科、美好医疗、爱朋医疗等近20只相关概念股涨停或涨超10%。其中，爱 朋医疗开盘后直线拉升，1分钟内就封死20%涨停板。 有分析指出，马斯克关于"Neuralink将于2026年启动脑机接口设备大规模量产"的公开表态，使得国内脑机接口 相关公司获得较高的市场关注度。不过，虽然脑机接口产业前景广阔，但不少公司的产品多处于临床阶段，仍 具备不确定性。短期来看，该板块热度过高，需注意部分个股的回调风险。 上述消息，是脑机接口概念股本轮行情的直接催化剂。国金证券表示，在此之前，市场普遍认为脑机接口技术 仍处于实验阶段，商业化前景 ...